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ABSTRACT 
Background: Propofol as an induction agent has disadvantage of pain on intravenous injection (IV). Objective: The aim of 
this study was to compare the efficacy of ramosetron and dexamethasone as a pretreatment drug for attenuation of pain due to 
propofol injection. Methods: This randomized comparative study was conducted at a tertiary care hospital in Eastern India, 
over a period of one year (March 2016-February 2017). Total 90 American Society of Anesthesiologists (ASA) grade I and II 
patients were randomly assigned into three groups (30 in each). Group R received 2 ml (0.3mg) of ramosetron, Group D 
received 2 ml (0.1mg/kg) of dexamethasone, and Group N received 2 ml of 0.9% normal saline. Venous drainage was 
occluded by using a tourniquet in mid-forearm before injecting the pre-treatment solution and released after 1 min and then 2 
ml of propofol was injected over 5 sec. Patients were observed and questioned 15 sec later, if they had pain in the arm or 
discomfort during drug injection. The pain was scored on a four-point scale: 0 = no pain, 1 = mild pain, 2 = moderate pain, 
and 3 = severe pain. Pearson’s Chi Square test/Fisher's Exact Test and Mann-Whitney U test/Kruskal Wallis Test were used to 
analyze the results. Results: The overall incidence of pain was 90% in the saline group, 17% in the ramosetron group and 10% 
in the dexamethasone group. The intensity of pain was significantly less in patients receiving ramosetron and dexamethasone 
than those receiving saline (P < 0.05). Haemodynamic parameters like heart rate (HR) and mean blood pressure (MBP) were 
recorded at different points of time. No significant inter group differences in MBP and HR were noted at any point of time. 
Conclusion: Pre-treatment with intravenous ramosetron and dexamethasone both lead to relief of pain on injection of IV 
propofol without any significant difference between their effects. 
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ropofol is a common intravenous (IV) anaesthetic 
drug used for induction and maintenance during 
general anaesthesia with rapid onset and short 
duration of action [1]. With the decrease in morbid adverse 
events after surgery, patient satisfaction with perioperative 
care is assuming more importance [2]. Pain on injection of 
anaesthetic is an important source of patient dissatisfaction 
and is a recognized adverse effect of propofol. Among 33 
low-morbidity clinical outcomes, considering clinical 
importance and frequency, pain during injection of 
propofol was ranked as the seventh most important 
problem of current clinical anaesthesiology by a panel of 
anaesthesiologists from academic and community 
practices, thus deserving high priority for improvement. In 
addition, the hyperdynamic cardiovascular response to the 
pain can precipitate adverse events in high- risk patients 
with history of coronary artery disease and/or abnormal 
heart rhythm [3]. The reported incidence of pain on 
injection of propofol varies between 28% and 90% in adult 
when injection given through small vein. Propofol, an 
alkyl phenol compound, is virtually insoluble in aqueous 
solution. Therefore it is formulated as emulsion containing 
1% (weight /vol) propofol, 10% soya bean oil, 2.25% 
glycerol & 1.2% purified egg phosphatid [4]. Propofol 
P 
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evokes pain on intravenous injection though its pH and 
osmolality are close to those of blood. Various 
interventions, both non pharmacological and 
pharmacological, have been tried to attenuate pain during 
intravenous injection of propofol. Non pharmacological 
strategies that have been employed include injection in a 
larger vein, injection in a fast running IV fluid, cooling 
propofol to 4 °C [5], diluting with 10% intralipid, injecting 
cold saline at 4 °C before propofol [5], different infusion 
rates, venous occlusion, different needle sizes, different 
injection sites and microfiltration [6]. In the 
pharmacological class of interventions, several classes of 
drugs like alpha2 agonists- dexmedetomidine [7], 
antiemetics- metoclopramide [8], barbiturates, 
cholinesterase inhibitors [9], kallikrein inhibitors, N-
methyl-D-aspartate (NMDA) receptor antagonists 
ketamine [7], magnesium sulphate [10], nitroglycerin [11], 
Non-steroidal anti-inflammatory drugs (NSAIDS) [12], 
opioids- tramadol [13], remifentanyl [14], steroids- 
dexamethasone [15], hydrocortisone [16], 
methylprednisolone [17], and local anesthesthetics- 
lidocaine [13], have been tried. 
Recently, 5‐hydroxytryptamine‐3 (5‐HT3) antagonists 
such as ondansetron, granisetron, ramosetron and 
palonosetron which are used as antiemetics, have been 
shown to effectively alleviate propofol‐induced pain 
individually [13,18-21]. Corticosteroids are systemic anti-
inflammatory agents [22], systemic analgesics and are 
known to block nociceptive C fibres when applied locally 
[23]. Dexamethasone has been shown to reduce propofol 
injection pain [7,23]. Despite some of the strategies 
showing promising results, none of the above-mentioned 
methods has been fully effective in attenuating the pain 
due to propofol injection and the research for the ideal 
agent or intervention, that would make anesthesia 
administration with propofol a pleasing experience, 
continues. In our practice, ramosetron and dexamethasone 
both are routinely used as premedication to prevent post- 
operative nausea and vomiting (PONV) in patients 
following general anesthesia.  
Ramosetron is a serotonin 5HT3 receptor antagonist 
and demonstrates superior efficacy and longer duration to 
ondansetron because of a slower rate of dissociation from 
the target receptor and higher binding affinity [24]. Since 
there is no data available regarding the effectiveness of 
ramosetron compared to dexamethasone presently, we 
decided to study the efficacy of ramosetron as pretreatment 
to attenuate the pain of propofol injection and to compare 
the results with IV pretreatment with dexamethasone and 
placebo.  
METHODS 
This randomized comparative study was conducted at a 
tertiary care hospital in Eastern India over a period of one 
year (March 2016-February 2017). We included 90 
patients belonging to American Society of 
Anesthesiologists (ASA) physical status (PS) I and II, of 
either sex, aged 18–60 years, weighing between 40 and 80 
kg, scheduled for various elective general and uro surgical 
procedures under general anesthesia. The patients were 
explained about the procedure during the pre-anesthetic 
visit. Exclusion criteria for the study were patient’s refusal, 
h/o allergy to propofol or 5HT3 receptor antagonist or 
corticosteroid, patients with known cardiac disorders, other 
systemic disorders of lungs and liver, pregnant patients, 
patients for emergency procedures, BMI>30kg/m2, ASA 
grades III-IV patients, patients with difficulty in 
communication and patients who had received analgesic 
drug within 12 hours prior to surgery. After obtaining 
Institutional ethical committee approval and informed 
written consent from patients, eligible patients were 
randomly allocated using computer generated -randomized 
test to one of three equal (30 in each group) groups: the 
two study groups (R and D) and the control group (N).  
  Patients were kept NPO for 8 hours and no analgesic 
was given 12 hours prior to surgery. On the day of surgery, 
after confirming patient’s identity and NPO status, patients 
were shifted to the operating room and connected to 
multiparameter monitor. Non-invasive blood pressure 
(NIBP), ECG, heart rate (HR), SPO2 and end tidal carbon 
dioxide, was monitored throughout the surgery. A 20G 
cannula was inserted into a vein on the dorsum of 
nondominant hand of the patient. One bottle of crystalloid 
solution was infused. Mean arterial blood pressure and HR 
were recorded for statistical comparison among the three 
groups at baseline, after pretreatment, after injecting full 
dose of propofol.  Patients in Group-R (n=30) , Group-D 
(n=30) and Group-N (n=30)  received 2 ml (0.3mg) of 
ramosetron, 2ml (0.1mg/kg) of dexamethasone and 2ml 
0.9% normal saline respectively over a period of 5 seconds 
through intravenous route.  
  All the drugs were prepared at the room temperature 
and the anaesthesiologist was unaware of its content. 
Venous drainage was occluded by using a tourniquet in 
mid-forearm before injection of pre-treatment solution  
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injection and maintained for 60 seconds. After the release 
of the tourniquet, initially a 2ml bolus of propofol was 
injected over 5 seconds. After 15 seconds of this injection, 
any complain of pain or discomfort by the patient, was 
elicited followed by giving rest of the induction dose. A 
researcher, who was unaware of group assignment, 
assessed the pain according to the verbal rating scale: 0 = 
none (negative response to questioning), 1=mild pain (pain 
reported only in response to questioning without any 
behavioural signs), 2=moderate pain (pain reported in 
response to questioning and accompanied by a behavioural 
sign or pain reported spontaneously without questioning), 
3= severe pain (strong vocal response or response 
accompanied by facial grimacing, arm withdrawal or 
tears). After propofol injection, and pain assessment, 
fentanyl 2 microgram/kg and atracrium 0.5 mg/kg were 
given. Intubation was done 3min after atracrium 
administration; Anesthesia was maintained by a mixture of 
nitrous oxide and oxygen supplemented with desflorane. 
Muscle relaxation was maintained by increments of 
atracrium. At the end of surgery reversal was done by 
giving injection neostigmine 0.04 mg/kg and glycopyrolate 
injection 0.01mg/kg through intravenous route. The data 
including HR, mean blood pressure (MBP) and pain 
during propofol injection were collected by a blinded 
observer and was analyzed statistically.  
 
Figure 1- CONSORT diagram showing division of patients at every stage of trial
 Based on the review of the literatures [11,23], 30 
patients were calculated as the minimum size for each 
group assuming an α-value of 0.05 and a power value of 
80%. The statistical software SPSS version 20 was used 
for the analysis. Categorical variables were expressed as 
number of patients and percentage of patients and 
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compared across the groups using Pearson’s chi square test 
for independence of attributes/Fisher’s exact tests, as 
appropriate. Continuous variables were expressed as mean 
± standard deviation and compared across the groups using 
Mann-whitney U test/Kruskalwallis test as appropriate. An 
alpha level of 5% had been taken that if any p value was < 
0.05 it had been considered as significant. 
RESULTS 
In total, 124 patients were screened for the study and 90 
patients were randomised into three groups. The flow of 
the patients enrolled was represented in the CONSORT- 
flow diagram (Figure 1). There was no significant 
difference in the demographic characteristics in all the 
three groups (Table 1 and 2). No patients in any group 
experienced pain and discomfort during the injection of 
pretreatment solution. The incidence of pain during IV 
injection of propofol in various groups is shown in Table 
3.  
The incidence of pain on injection of propofol in the saline 
(N) group was 90% (27/30), as compared to 17% (5/30) in 
ramosetron (R) group and 10% (3/30) in dexamethasone 
(D) group. The incidence of pain was significantly less (P 
< 0.05) in patients receiving drugs for pre-treatment than 
those receiving saline. Mild pain was observed in 3 (10%) 
and 2 (6%) patients in Groups R and D, respectively, as 
compared to 10 (33%) patients in N group. Moderate pain 
was observed in 2 (6%) and 1 (3%) patients in Groups R 
and D respectively as compared to 12 (40%) patients in N 
group. None of the study groups’ patients felt any severe 
pain as compared to control group (17%). Significant 
difference in mean pain score were observed between 
group R and N (P < 0.001) and group D and N (P < 0.001), 
but not between R and D (Table 4). Regarding 
haemodynamic parameters, no significant inter group 
differences in HR and MBP were noted at any point of 
time (Table 5). 
Table 1 - Comparison of Age and Body weight among three groups 
Parameters Group R (n=30) Group D (n=30) Group N (n=30) P Value 
Mean±SD Mean±SD Mean±SD Over all R vs D R vs N D vs N 
Age (years) 42.7±1.64 43±1.55 42.33±1.67 0.272 0.494 0.366 0.107 
Weight (kg) 60.4±7.16 61.97±6.47 60.43±5.2 0.455 0.542 0.835 0.124 
 
Table 2 - Comparison of Sex among three groups  
Table 3 - Incidence and intensity of pain following Propofol injection 
Pain experienced Group R               Group D                   Group N                P Value           
No pain (>05
#
) 25 ( 83)               27 (90)                 3 (10)                 < 0.05* 
Pain 5 (17)   3 (10)               27(90)            < 0.05* 
Mild Pain (>05
#
) 3 (10) 2 (6) 10 (33) <0.05* 
Moderate pain 2 (6) 1 (3) 12 (40) <0.05* 
Severe Pain 0 0 5 (16) <0.05* 
Data is expressed as number of patients (%). *P -value between Group N and Group R & D.  
#
P -value between Group R and D 
Table 4 - Comparison of mean pain score (VAS) among three groups 
Pain    score (VAS) P Value 
Group R Group D Group N 
Mean±SD Mean±SD Mean±SD Over all R vs D R vs N D vs N 
0.2±0.48 0.1±0.31 1.67±0.88 ≤0.001 0.430 ≤0.001 ≤0.001 
Sex Groups, n (%) Total P Value 
Group R (n=30) Group D (n=30) Group N(n=30) Over all R vs D R vs N D vs N 
Female 8 (26.67) 10 (33.33) 9 (30) 27 (30) 0.957 0.779 0.774 0.781 
Male 22 (73.33) 20 (66.67) 21(70) 63 (70) 
Total 30(100) 30(100) 30(100) 90(100) 
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Table 5 - Comparison of Heart Rate & Mean blood pressure among three groups 
Parameters Group R Group D Group N                             P Value 
Mean±SD Mean±SD Mean±SD Over all R vs D R vs  N D vs  N 
Base Line HR 83.43±9.1 82.43±7.61 83.2±6.97 0.693 0.434 0.532 0.732 
HR: After Pretreatment 79.1±9.35 82.2±7.44 80.87±7.28 0.412 0.229 0.458 0.403 
HR: After Injecting Full dose Of propofol 90.63±8.3 93.1±5.7 93.23±6.51 0.513 0.368 0.288 0.801 
Baseline MBP 96.18±5.26 98.07±5.34 96.23±5.59 0.393 0.219 0.923 0.257 
MBP: After Pretreatment 94.58±5.29 94.44±5.11 96.51±5.37 0.277 0.882 0.115 0.245 
MBP: After injecting full dose of propofol 82.12±4.95 83.77±4.26 83.29±5.04 0.309 0.166 0.242 0.615 
HR: Heart Rate (in beats/ minute); MBP: Mean Blood Pressure (in mm-Hg) 
 
DISCUSSION 
Propofol is the drug of choice for induction of anaesthesia 
in millions of patients every year because of its rapid onset 
and short duration of action, easy titration, and favourable 
profile for side effects [1].Considering the extensive use of 
propofol in clinical practice, the pain frequently reported 
on induction of anaesthesia cannot be neglected. 
Chemically, propofol belongs to the group of sterically 
hindered phenols. It is no wonder that during intravenous 
injection propofol like any other phenol will be irritating 
the skin, mucous membrane and venous intima [6]. As the 
underlying mechanism of pain is not fully understood, a 
number of hypotheses have been put forward to explain the 
propofol induced pain. The immediate vascular pain on 
propofol injection is attributed to a direct irritant effect of 
the drug by stimulation of venous nociceptive receptors or 
free nerve endings involving myelinated Aδ fibres .The 
delayed pain of injection has a latency of 10–20 s mediated 
by activation of kallikrein–kinin system [12]. 
 The most important finding of this study was the 
reduction in the number of patients who reported moderate 
or severe pain following propofol administration, when 
pretreated with ramosetron and dexamethasone compared 
to saline. 5-HT3 receptor antagonists have been widely 
used as anti- emetics. Ondansetron, a 5-HT3 receptor 
antagonist, blocked the sodium channel in an animal study, 
and had a 15-fold-higher local anesthetic efficacy than 
lidocaine. In addition, as 5-HT3 receptor antagonists act as 
agonists by combining with the μ receptor, and as 
peripheral 5-HT3 receptors are involved in the nociceptive 
pathway, the 5-HT3 receptor antagonist results in an 
analgesic effect. Descending monoaminergic pathways 
from brainstem are known to able to influence nociceptive 
signaling in the dorsal horn of the spinal cord. Such 
descending influences are both facilitatory and inhibitory 
in nature. Suzuki and colleagues [25] showed that the 
descending influences are predominantly facilitatory, and 
act via spinal 5-HT3 receptors (expressed on nerve 
terminals of small diameter afferents), revealing a role for 
selective 5-HT3 receptor antagonists like ondansetron and 
granisetron in relieving pain. 
 Ramosetron is a tetrahydro‐benzimidazole derivative 
structurally independent of previously developed drugs 
such as ondansetron, granisetron and tropisetron. 
Ramosetron is more potent and has longer lasting effects 
because of a slower rate of dissociation from the target 
receptor and higher binding affinity[24]. Ramosetron has 
been used during anaesthesia induction or before the end 
of surgery to prevent nausea and vomiting after surgery or 
anti-cancer treatment [26,27]. The present study showed 
incidence of propofol injection pain was 17% (5/30) in 
ramosetron (R) group as compared to in the saline (N) 
group was 90% (27/30). Only 3 (10%) patients in D group 
and 2 (6%) patients in R group complained of mild and 
moderate pain respectively in comparison to the control 
group N (33% and 40%).  
 The result was consistent with the study done by 
Basappa G and colleagues [28] who studied the effect of 
lignocaine, ondansetron and ramosetron on attenuation of 
propofol injection induced pain. The study concluded that 
pre- treatment with IV ramosetron 0.3mg is equally 
effective as 0.5mg/kg of 2% lignocaine in preventing 
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propofol induced pain and both were better than 
ondansetron. Singh D et al [18] compared the incidence of 
pain induced by propofol injection in patients pre-treated 
with ramosetron with those pre-treated with lidocaine, 
concluded that pre-treatment with ramosetron 0.3mg and 
lidocaine 40mg are equally effective in preventing pain 
from propofol injection, which is consistent with the 
results of present study. Lee HY et al [29] investigated the 
effect of ramosetron on pain induced by microemulsion 
propofol injection on 200 ASA I and II patients 
undergoing general anesthesia. They found that incidence 
of pain was 96%, 76%, 60% and 38% in patients receiving 
normal saline, lidocaine 20mg, ramosetron 0.3mg and 
lidocaine 20mg plus ramosetron 0.3mg, respectively 
(p<0.008). The study concluded that pretreatment with 
ramosetron 0.3mg with or without lidocaine 20mg with a 
tourniquet on the forearm 30 seconds before the injection 
of microemulsion propofol is more effective than lidocaine 
20mg or normal saline in preventing pain from a 
microemulsion propofol injection.  
 In the current study, it was found that 27 patients 
(90%) in D group had no pain. In contrast, the number of 
patients without pain in N group was 3(10%). There was 
significant decrease in moderate and severe pain in group 
D (1% and nil in each) compared with normal saline group 
(40% and 16%, respectively). A previous study found that 
31% of patients felt pain (P < 0.01) after dexamethasone 
pre-treatment and moderate to severe pain was noticed in 
17.14% [30]. Another study comparing lignocaine, 
pethidine and dexamethasone as pre-treatment found that 
48% of the patients with dexamethasone pre-treatment had 
no pain [31]. The combination of lignocaine 20 mg and 
dexamethasone 6 mg with venous occlusion for 1 min was 
more effective than lignocaine 20 mg (34.3%) or 
dexamethasone 6 mg (37.1%) alone for pain control during 
propofol injection [23]. Dexamethasone given at higher 
analgesic doses reduces pain associated with the injection 
of propofol [3]. These results showed an effective 
reduction in the incidence and severity of propofol 
injection pain after pre-treatment with dexamethasone 
which was similar to our study. Patel M, et al also 
concluded in their study that pretreatment with iv 
lignocaine 0.5mg/kg, ondansetron 0.1mg/kg, 
dexamethasone 0.1mg/kg in preventing pain from propofol 
injection were better than cold propofol per se [32]. 
 Propofol has been shown to release nitric oxide (NO) 
from vessels in animals and humans, and the release of 
nitric oxide has been linked to the generation of pain in the 
veins in human. In addition, NO from the vascular 
endothelium binds to guanyl cyclase this catalyzes the 
conversion of guanosine triphosphate to guanosine 
monophosphate, which facilitates PGE2-induced 
hyperalgesia. It has been found that pain following 
intravenous injection of bradykinin and hyperosmolar 
solutions can be blocked by pretreatment with NO 
synthase (NOS) inhibitor, suggesting that an intact NOS 
pathway is needed to elicit vascular nociception. The 
effects of corticosteroids such as dexamethasone on NO 
production have been previously demonstrated. In 
addition, the efficacy of steroids to alter nitric oxide 
release has also been demonstrated in several disease 
conditions [33,34] .Therefore, the choice of 
dexamethasone to minimize propofol-induced vascular 
pain was not only based on its wide clinical utilization but 
also due to its biological basis. 
 In the current study, though we found that ramosetron 
and dexamethasone significantly reduced the occurrence 
and severity of pain due to propofol injection in 
comparison to placebo, we could not find any significant 
difference in mean pain score between these two drugs (P 
< 0.430). No significant inter group differences in MBP 
and HR were noted at any point of time. The present study 
proved that intravenous ramosetron besides its antiemetic 
action can effectively attenuate the pain on injecting IV 
propofol equally as dexamethasone. However, the choice 
of agent should, therefore, be individualized with due 
consideration to the cost‐effectiveness and benefit to the 
patient.  There were few limitations to this study; the 
outcome of this study may not be applicable in emergency 
induction. This technique is useful in elective surgery and 
adult participants.  
 A limitation of all studies evaluating propofol injection 
pain is the use of a subhypnotic dose of propofol so that 
reliable pain assessments reporting can be obtained. 
Finally, our study was underpowered to detect the 
difference in the incidence of moderate to severe pain 
between ramosetron and dexamethasone.  
CONCLUSION 
The analgesic efficacy of ramosetron given as pre-
treatment with propofol is as effective as dexamethasone 
in preventing propofol-induced pain and both have an 
added advantage of preventing PONV. 
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